MA48765A - Cyanopyrrolidines substituées par sulfonamide ayant une activité en tant qu'inhibiteurs de dub - Google Patents
Cyanopyrrolidines substituées par sulfonamide ayant une activité en tant qu'inhibiteurs de dubInfo
- Publication number
- MA48765A MA48765A MA048765A MA48765A MA48765A MA 48765 A MA48765 A MA 48765A MA 048765 A MA048765 A MA 048765A MA 48765 A MA48765 A MA 48765A MA 48765 A MA48765 A MA 48765A
- Authority
- MA
- Morocco
- Prior art keywords
- activity
- sulfonamide substituted
- dub inhibitors
- cyanopyrrolidines
- substituted cyanopyrrolidines
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/14—Nitrogen atoms not forming part of a nitro radical
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pain & Pain Management (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Rheumatology (AREA)
- Obesity (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Pyrrole Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB1708652.1A GB201708652D0 (en) | 2017-05-31 | 2017-05-31 | Novel compounds and uses |
Publications (1)
Publication Number | Publication Date |
---|---|
MA48765A true MA48765A (fr) | 2020-04-08 |
Family
ID=59270941
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MA048765A MA48765A (fr) | 2017-05-31 | 2018-05-30 | Cyanopyrrolidines substituées par sulfonamide ayant une activité en tant qu'inhibiteurs de dub |
Country Status (7)
Country | Link |
---|---|
US (1) | US11414402B2 (fr) |
EP (1) | EP3630096A1 (fr) |
JP (1) | JP7221217B2 (fr) |
CN (1) | CN110678176B (fr) |
GB (1) | GB201708652D0 (fr) |
MA (1) | MA48765A (fr) |
WO (1) | WO2018220355A1 (fr) |
Families Citing this family (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3519385B1 (fr) | 2016-09-27 | 2020-11-18 | Mission Therapeutics Limited | Dérivés de cyanopyrrolidine ayant une activité en tant qu'inhibiteurs de l'usp 30 |
GB201616511D0 (en) | 2016-09-29 | 2016-11-16 | Mission Therapeutics Limited | Novel compounds |
GB201616627D0 (en) | 2016-09-30 | 2016-11-16 | Mission Therapeutics Limited | Novel compounds |
TWI771327B (zh) | 2016-10-05 | 2022-07-21 | 英商使命醫療公司 | 新穎化合物 |
EP3642196B1 (fr) | 2017-06-20 | 2022-08-17 | Mission Therapeutics Limited | Cyanopyrrolidines substituées présentant une activité en tant qu'inhibiteurs de dub |
EA202090871A1 (ru) | 2017-10-06 | 2020-07-03 | Форма Терапьютикс, Инк. | Ингибирование убиквитин-специфической пептидазы 30 |
EP4218934A1 (fr) | 2018-10-05 | 2023-08-02 | Forma Therapeutics, Inc. | Inhibition de la protéase 30 spécifique de l'ubiquitine (usp30) |
WO2020159576A1 (fr) | 2019-01-28 | 2020-08-06 | Mitochondria Emotion, Inc. | Activateurs de la mitofusine et leurs procédés d'utilisation |
WO2020159797A1 (fr) | 2019-01-28 | 2020-08-06 | Mitochondria Emotion, Inc. | Activateurs de dérivés trans-4-hydroxycyclohexylphénylamide de la mitofusine et leurs méthodes d'utilisation |
GB201905371D0 (en) | 2019-04-16 | 2019-05-29 | Mission Therapeutics Ltd | Novel compounds |
GB201905375D0 (en) | 2019-04-16 | 2019-05-29 | Mission Therapeutics Ltd | Novel compounds |
GB201912674D0 (en) | 2019-09-04 | 2019-10-16 | Mission Therapeutics Ltd | Novel compounds |
EP4132925A1 (fr) | 2020-04-08 | 2023-02-15 | Mission Therapeutics Limited | N-cyanopyrrolidines ayant une activité en tant qu'inhibiteurs de l'usp30 |
CN115667252A (zh) | 2020-05-28 | 2023-01-31 | 特殊治疗有限公司 | 用于治疗线粒体功能障碍的作为usp30抑制剂的n-(1-氰基-吡咯烷-3-基)-5-(3-(三氟甲基)苯基)噁唑-2-甲酰胺衍生物和对应噁二唑衍生物 |
AU2021285130A1 (en) | 2020-06-04 | 2023-01-19 | Mission Therapeutics Limited | N-cyanopyrrolidines with activity as USP30 inhibitors |
BR112022024794A2 (pt) | 2020-06-08 | 2022-12-27 | Mission Therapeutics Ltd | Hexahidropirrolo[3,4-b]pirrolo-5(1h)-carbonitrilas com atividade como inibidores de usp30 para uso no tratamento de disfunção mitocondrial, câncer e fibrose |
GB202016800D0 (en) | 2020-10-22 | 2020-12-09 | Mission Therapeutics Ltd | Novel compounds |
WO2022159566A1 (fr) * | 2021-01-21 | 2022-07-28 | Icahn School Of Medicine At Mount Sinai | Benzènesulfonamides comme agonistes de trap1 pour le traitement d'une fibrose d'organe |
WO2023099561A1 (fr) | 2021-12-01 | 2023-06-08 | Mission Therapeutics Limited | N-cyanopyrrolidines substituées ayant une activité en tant qu'inhibiteurs de l'usp30 |
Family Cites Families (30)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2404630A1 (fr) * | 2000-04-06 | 2001-10-18 | Merck Frosst Canada & Co. | Inhibiteurs de proteases a cysteine de type cathepsines |
US6867221B2 (en) | 2001-08-30 | 2005-03-15 | Kowa Co., Ltd. | Cyclic amine compounds and pharmaceutical composition containing the same |
AU2006306367A1 (en) | 2005-10-21 | 2007-05-03 | Vertex Pharmaceuticals Incorporated | Derivatives for modulation of ion channels |
CA2689989A1 (fr) | 2007-06-04 | 2008-12-11 | Avila Therapeutics, Inc. | Composes heterocycliques et utilisations de ceux-ci |
PE20090606A1 (es) * | 2007-08-20 | 2009-06-17 | Glaxo Group Ltd | Nuevos inhibidores de catepsina c y uso |
WO2009129371A1 (fr) * | 2008-04-18 | 2009-10-22 | Glaxo Group Limited | Inhibiteurs de la cathepsine c |
TW201002318A (en) * | 2008-04-18 | 2010-01-16 | Glaxo Group Ltd | Cathepsin C inhibitors |
WO2009129370A1 (fr) | 2008-04-18 | 2009-10-22 | Glaxo Group Limited | Inhibiteurs de la cathepsine c |
EP2565186A1 (fr) | 2011-09-02 | 2013-03-06 | Hybrigenics S.A. | Inhibiteurs sélectifs et réversibles de la protéase 7 spécifique de l'ubiquitine |
CN103183673B (zh) | 2011-12-30 | 2016-09-14 | 浙江新和成股份有限公司 | (s,s)-2,8-二氮杂双环[4,3,0]壬烷的合成方法 |
HUE042111T2 (hu) | 2013-07-31 | 2019-06-28 | Merck Patent Gmbh | Piridinek, pirimidinek és pirazinok mint BTK inhibitorok, továbbá ezek alkalmazása |
WO2015179190A1 (fr) | 2014-05-19 | 2015-11-26 | Northeastern University | Inhibiteurs d'amidase acide (naaa) hydrolysant la n-acyléthanolamine et leur utilisation |
US20170095457A1 (en) | 2014-05-27 | 2017-04-06 | David Lonergan | Compositions and methods of delivery of deubiquitinase inhibitors |
WO2016019237A2 (fr) | 2014-07-31 | 2016-02-04 | Pharmacyclics Llc | Inhibiteurs de la tyrosine kinase de bruton |
GB201416754D0 (en) * | 2014-09-23 | 2014-11-05 | Mission Therapeutics Ltd | Novel compounds |
RS61759B9 (sr) * | 2015-03-30 | 2021-11-30 | Mission Therapeutics Ltd | Jedinjenja 1-cijano-pirolidina kao inhibitori usp30 |
CN107849013B (zh) * | 2015-07-14 | 2022-03-29 | 特殊治疗有限公司 | 作为dub抑制剂用于治疗癌症的氰基吡咯烷类 |
GB201521109D0 (en) | 2015-11-30 | 2016-01-13 | Mission Therapeutics Ltd | Novel compounds |
GB201522267D0 (en) | 2015-12-17 | 2016-02-03 | Mission Therapeutics Ltd | Novel compounds |
GB201522768D0 (en) | 2015-12-23 | 2016-02-03 | Mission Therapeutics Ltd | Novel compounds |
GB201602854D0 (en) | 2016-02-18 | 2016-04-06 | Mission Therapeutics Ltd | Novel compounds |
GB201603779D0 (en) | 2016-03-04 | 2016-04-20 | Mission Therapeutics Ltd | Novel compounds |
GB201604638D0 (en) | 2016-03-18 | 2016-05-04 | Mission Therapeutics Ltd | Novel compounds |
GB201604647D0 (en) | 2016-03-18 | 2016-05-04 | Mission Therapeutics Ltd | Novel compounds |
US11352339B2 (en) | 2016-03-24 | 2022-06-07 | Mission Therapeutics Limited | 1-cyano-pyrrolidine derivatives as DUB inhibitors |
EP3519385B1 (fr) | 2016-09-27 | 2020-11-18 | Mission Therapeutics Limited | Dérivés de cyanopyrrolidine ayant une activité en tant qu'inhibiteurs de l'usp 30 |
GB201616511D0 (en) | 2016-09-29 | 2016-11-16 | Mission Therapeutics Limited | Novel compounds |
GB201616627D0 (en) | 2016-09-30 | 2016-11-16 | Mission Therapeutics Limited | Novel compounds |
TWI771327B (zh) | 2016-10-05 | 2022-07-21 | 英商使命醫療公司 | 新穎化合物 |
EP3642196B1 (fr) | 2017-06-20 | 2022-08-17 | Mission Therapeutics Limited | Cyanopyrrolidines substituées présentant une activité en tant qu'inhibiteurs de dub |
-
2017
- 2017-05-31 GB GBGB1708652.1A patent/GB201708652D0/en not_active Ceased
-
2018
- 2018-05-30 JP JP2019561718A patent/JP7221217B2/ja active Active
- 2018-05-30 CN CN201880035657.8A patent/CN110678176B/zh active Active
- 2018-05-30 MA MA048765A patent/MA48765A/fr unknown
- 2018-05-30 WO PCT/GB2018/051454 patent/WO2018220355A1/fr active Application Filing
- 2018-05-30 US US16/615,040 patent/US11414402B2/en active Active
- 2018-05-30 EP EP18730047.0A patent/EP3630096A1/fr active Pending
Also Published As
Publication number | Publication date |
---|---|
US20200172518A1 (en) | 2020-06-04 |
GB201708652D0 (en) | 2017-07-12 |
WO2018220355A1 (fr) | 2018-12-06 |
JP2020521730A (ja) | 2020-07-27 |
CN110678176A (zh) | 2020-01-10 |
CN110678176B (zh) | 2023-03-14 |
EP3630096A1 (fr) | 2020-04-08 |
JP7221217B2 (ja) | 2023-02-13 |
US11414402B2 (en) | 2022-08-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MA48765A (fr) | Cyanopyrrolidines substituées par sulfonamide ayant une activité en tant qu'inhibiteurs de dub | |
MA52486A (fr) | Pyridazinones utilisés en tant qu'inhibiteurs de parp7 | |
CA188844S (fr) | Collier | |
DK3612531T3 (da) | Apoptose-inducerende midler | |
MA44725A (fr) | Formulations d'un inhibiteur de lsd1 | |
MA52413A (fr) | Inhibiteurs de cd73 | |
CA189123S (fr) | Collier | |
DK3687994T3 (da) | Gadolinium-bærende pcta-baserede kontrastmidler | |
MA40774A (fr) | Dérivés de diaryle-urée en tant qu'inhibiteurs de kinase p38 | |
MA41140A (fr) | Dérivés de 2,4-dioxo-quinazoline-6-sulfonamide en tant qu'inhibiteurs de la parg | |
EA201791684A1 (ru) | Селективные ингибиторы bace1 | |
MA46878A (fr) | Composés de benzodiazolium en tant qu'inhibiteurs d'enac | |
UA37876S (uk) | Трактор | |
MA47736A (fr) | Pyrimidopyrimidinones utiles en tant qu'inhibiteurs de la kinase wee-1 | |
EA201790432A1 (ru) | Зонды для визуализации белка хантингтина | |
MA49006A (fr) | Inhibiteurs d'ip6k | |
DK3459601T3 (da) | Sprinklerhoved | |
FR3050174B1 (fr) | Combinaison pour activite aquatique | |
MA41174A (fr) | Dérivés d'imidazopyridazine utilisés en tant qu'inhibiteurs de pi3kbeta | |
DK3452093T3 (da) | Ophthalmiske sammensætninger | |
ITUB20153201A1 (it) | Kit per la chirurgia episclerale. | |
DK3412667T3 (da) | Cokrystal | |
CA187946S (fr) | Collier | |
IT201700035964A1 (it) | “divisorio per boiserie” | |
ITUA20163609A1 (it) | "micro-cogeneratore". |